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Why does this 
strategy exist?   
ZKDW¶VWKH
problem/opportunity 
this stems from)  
Key Drivers of global Life Sciences Industry are:  
x changing global demographics are driving demand for healthcare for the 
young and old, the largest consumers of health care products and 
services.  
x continued downward pressure on the cost of drugs, through growing 
political pressure to reduce prices and the growth of the generics drug 
market.  
x Scotland lacks critical mass for the sector - with one multinational 
pharmaceutical research site and the absence of a global pharmaceutical 
headquarters   
x there are relatively poor transport links to other major international life 
sciences locations, particularly the USA, and   
x within the supply and support sub-sector, many of the large companies 
present in the Scottish life sciences sector are under foreign ownership. 
While this in itself is not necessarily a problem, it is essential that this 
investment base is maintained.  
Summary:  The aim of this strategy is a globally focused, sustainable life sciences sector built 
on a fully connected national strategy that exploits strengths in scientific 
excellence, financial services and innovative business models and that develops, 
retains and builds upon Scotland's talents. Over the next 15 years, we want the 
sector to continue increasing in size by a combination of new Scottish companies 
and attracting investment from outside. The aim is not merely more firms but, 
more importantly, shifting the balance towards a larger proportion of bigger, 
established, sustainable and profitable enterprises that can fund research and, 
over time, be sources of ideas, skills and investment for new ventures.  
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Key goals and 
means to achieve 
them:  
To accelerate growth, we will:   
x build on our scientific strengths   
x ZRUNWRJHWKHUWRHQJDJH6FRWODQG¶VVWURQJILQDQFLDOVHUYLFHVVHFWRUPRUH
fully whilst opening up channels of investment from elsewhere   
x promote and publicise success stories, and  
x respond to a world in which alliances, networks, outsourcing and 
partnerships play increasing roles alongside large integrated life sciences 
firms and healthcare providers.  
The ability to achieve this will depend on four vital and inter-related factors:  
x the right people: Scotland must create, attract and retain the best talent 
because of all the key ingredients for success, the most important is 
people. Young people must be attracted to study life science, keep bright 
graduates in Scotland and attract academics from around the world.  
x the right resources: It is important that appropriate resources are behind 
this, including financial, management and business skills, physical 
infrastructure and access to information and market intelligence  
x focus: there is a need to concentrate our activity and resources on fully 
exploiting those opportunities to which Scottish companies and institutions 
add greatest value. The public sector and the research community are 
increasingly focusing effort and engaging with business in those areas 
where Scotland can secure and maintain a competitive edge. In this 
research intensive industry, the imbalance in R&D spending in Europe 
compared to the US is a cause of concern. To counter this imbalance, 
business development and growth must be boosted, and new synergies 
must be created and exploited by building partnerships, allowing 
companies to identify and enter markets. This must be backed up by 
advanced infrastructure, improved access to capital and effective 
partnership with the public sector to drive local and national policy.  
x collaboration: The establishment of a cross-functional Life Sciences 
Alliance across industry, academia, NHSScotland and public sector 
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support organisations will provide a vehicle to drive forward the 
industU\¶V aspirations.   
Expected outcomes:  1. Increasing the contribution by life science companies to the Scottish 
economy.  
2. Being a more attractive place for life science graduates and experienced 
senior managers to work.  
3. Increasing the level of investment in life science, including attracting lead, 
expert investors into the country.  
4. Attracting added value foreign direct investment.  
5. Promoting and enhancing academic success.  
6. Demonstrating improved connectivity and collaboration among the 
stakeholders in the country  
Key quotes:  x The global life sciences market is valued at some $600 billion (2002), and 
continues to be dominated by the mature US market, which generates almost 
twice the revenue of Europe.  
x In the biotechnology sub-sector of life sciences, Scotland with less than 
10% of the UK population, accounts for approximately 15% of the total 
companies, and 10% of the total employment within the sector  
x Higher Education investment in research per capita in Scotland is 40% 
more than the rest of the UK. This is reflected in excellent performance as 
measured by scientific citations, Research Assessment Exercise outcomes, 
and a significantly higher proportion of life sciences graduates.  
x Universities and research institutes are already actively collaborating with 
LQGXVWU\DQGRWKHUUHVHDUFKHVWDEOLVKPHQWV7KH8QLYHUVLW\RI'XQGHH¶V'677
Consortium involving 6 pharmaceutical companies in a £15 million investment 
into kinase research is an excellent example.  
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x during the 5 years to 2004 the life science sector doubled in size in terms 
of employment and the number of firms.  
Parent/child 
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